Phase 3 Triple-Negative Breast Cancer Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Phase 3
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Triple-Negative Breast Cancer
Fudan University134 enrolled1 locationNCT05806060
Recruiting
Phase 3
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
TNBC - Triple-Negative Breast Cancer
West China Hospital318 enrolled1 locationNCT06627712
Recruiting
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832
Recruiting
Phase 3
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University606 enrolled1 locationNCT05862064
Recruiting
Phase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
Fudan University424 enrolled2 locationsNCT05999149
Recruiting
Phase 3
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Triple-Negative Breast Cancer
Fudan University223 enrolled1 locationNCT05760378